Galectin Therapeutics, the leader in developing carbohydrate-based therapeutic compounds to inhibit galectin proteins for the therapy of liver fibrosis and cancer, today announced that the first patient has been dosed in a Phase 1/2 trial evaluating the safety and efficacy of a novel treatment combination for the treatment of advanced ...

(San Diego Biotechnology Connection) Researchers at Emory University used a standard balloon angioplasty catheter to induced transient ischemia, which when coupled with the vasodilator nitroglycerin, boosts the cell transfection of an adenovector gene construct into heart cells.

(Children's Hospital of Philadelphia) A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma. A phase 1 clinical trial of the ...

TUESDAY, May 15 (HealthDay News) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease. The best-scenario hope is that the drug will lead to a way of preventing the progressive brain-wasting disease, and to a better understanding of its destructive processes, ...

The University of Virginia School of Medicine has launched the first U.S. outpatient trial of a UVA-developed artificial pancreas that could make it easier for type 1 diabetes patients to manage their condition.

A national, phase II clinical trial examining the effects of resveratrol on individuals with mild to moderate dementia due to Alzheimer's disease has begun as more than two dozen academic institutions recruit volunteers in the coming months. R. Scott Turner, M.D., Ph.D., director of Georgetown University Medical Center's Memory Disorders ...

Piramal Healthcare Bio-Orthopaedics, a division of Piramal Healthcare Limited, today announced that positive data from their pivotal (Phase III) clinical trial is being presented in 3 podium presentations as well as during an Industry Symposium at the 10th World Congress of the International Cartilage Repair Society (ICRS), May 12 to ...

THURSDAY, May 10 (HealthDay News) -- A new weight-loss drug that is awaiting approval from the U.S. Food and Drug Administration showed promising results in a recent international trial, researchers report. Volunteers who took Qnexa, a combination of the drugs phentermine and topiramate, experienced substantial weight loss, even if ...

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today final results from its completed Phase I clinical trial with ALN-TTR01, an RNAi therapeutic targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis.

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

Cell therapy demonstrates high rate of complete closure of hard-to-heal wounds, including diabetic foot (DFU) and venous ulcers.

"A vaccine against one of the most neglected yet fatal tropical diseases is being tested for the first time in a clinical trial in India and the U.S.," IRIN reports. Visceral leishmaniasis (VL), "also called kala-azar or black fever, infects an estimated half million persons or more annually," and "it ...